US4269828A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Indole anti-inflammatory composition
Assignee: Procter and Gamble Co
•
Filing: 1978-07-13
•
Granted: 1981-05-26
•
Expires: 1998-07-13
Abstract
Abstract The anti-inflammatory activity of indomethacin, indoxole, and other indole-based drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl 2 MDP.
Inventors
- 👤 Lawrence Flora
- 👤 Marion D. Francis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 04:21
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/66; A61K31/662; A61K31/663; A61P; A61P25/00; A61P25/04; A61P29/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
181 words
A method for treating or preventing pain and inflammation in animal tissues, comprising administering to an animal in need of such treatment from about 50 milligrams to about 6000 milligrams per day of an indole-based anti-inflammatory compound selected from indomethacin and pharmaceutically acceptable salts and esters thereof and from about 200 milligrams to about 2000 milligrams per day of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR6## or pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --C 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 2
Independent Claim
181 words
A method for treating or preventing pain and inflammation in animal tissues, comprising administering to an animal in need of such treatment from about 50 milligrams to about 6000 milligrams per day of an indole-based anti-inflammatory compound selected from indomethacin and pharmaceutically acceptable salts and esters thereof and from about 200 milligrams to about 2000 milligrams per day of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR6## or pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --C 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 3
Dependent Claim
41 words
A method according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid, and the pharmaceutically-acceptable salts thereof; dichloromethanediphosphonic acid, and the pharmaceutically-acceptable salts thereof; and methanediphosphonic acid, and the pharmaceutically-acceptable salts thereof.
Claim 4
Dependent Claim
12 words
A method according to claim 2 wherein the animal is a human.
Claim 5
Dependent Claim
31 words
A method according to claim 3 which employs a safe and effective amount of indomethacin and a safe and effective amount of dichloromethanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 6
Dependent Claim
31 words
A method according to claim 3 which employs a safe and effective amount of indomethacin and a safe and effective amount of ethane-1-hydroxy-1,1-diphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 7
Dependent Claim
31 words
A method according to claim 3 which employs a safe and effective amount of indomethacin and a safe and effective amount of methanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 8
Dependent Claim
168 words
A composition of matter for treating pain and inflammation in animal tissue, comprising from about 10 milligrams to about 500 milligrams of an indole-based anti-inflammatory compound selected from indomethacin and pharmaceutically acceptable salts and esters thereof and from about 50 milligrams to about 250 milligrams of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR7## or pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 9
Dependent Claim
168 words
A composition of matter for treating pain and inflammation in animal tissue, comprising from about 10 milligrams to about 500 milligrams of an indole-based anti-inflammatory compound selected from indomethacin and pharmaceutically acceptable salts and esters thereof and from about 50 milligrams to about 250 milligrams of an organophosphonate compound selected from the group consisting of geminal organophosphonates of the formula ##STR7## or pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R 3 is selected from the group consisting of H, C 1 -C 20 alkyl or cycloalkyl, C 2 -C 20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH) or --CH 2 CH(PO 3 H 2 ) 2 ; and R 4 is selected from the group consisting of H, lower alkyl, amino, benzyl, halogen, --OH, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 CH 2 PO 3 H 2 .
Claim 10
Dependent Claim
41 words
A composition according to claim 7 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid, and the pharmaceutically-acceptable salts thereof; dichloromethanediphosphonic acid, and the pharmaceutically-acceptable salts thereof; and methanediphosphonic acid, and the pharmaceutically-acceptable salts thereof.
Claim 11
Dependent Claim
30 words
A composition according to claim 7, comprising a safe and effective amount of indomethacin and a safe and effective amount of dichloromethanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
Claim 12
Dependent Claim
30 words
A composition according to claim 7, comprising a safe and effective amount of indomethacin and a safe and effective amount of methanediphosphonic acid, or the pharmaceutically-acceptable salts or esters thereof.
References Cited (Backward Citations)
US3553314A
Cited
US3584125A
Cited
US3553315A
Cited
US3584124A
Cited
US3678164A
Cited
US3641246A
Cited
US3662066A
Cited
US3683080A
Cited
US4044125A
Cited
US4049803A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-05-25 | 1984-11-24 | 1985-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-05-25 | 1988-11-24 | 1989-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-05-25 | 1992-11-24 | 1993-05-26 | $7700.00 | Window Closed / Lapsed |